Avanir Pharmaceuticals Inc. (AVNR) Accepted for “Late Breaking Science” Presentation
As the 2011-12 patent drop-off for a majority of solid selling pharma products approaches, and phase III trial products are watched even more closely by the larger pharma companies, a solid report here or there can only boost value in a company. As the FDA vary rarely telegraphs its likelihood of acceptance for a new drug product, placing an investment on a pharma research company is still a risk. But if the investment pans out, it could provide a very large return. Avanir Pharmaceuticals Inc., a biopharmaceutical company, focuses on acquiring, developing and commercializing drug candidates directed primarily at the…